Oticon Medical has been honoured with the Hearing Technology Innovator Award™ in the category of Auditory Implants: Bone Conduction for its Sentio System. The award, presented at the fifth annual Hearing Technology Innovator Awards™, recognises groundbreaking advancements in the hearing industry.
Hosted by Hearing Health & Technology Matters (HHTM), the annual awards celebrate technological innovations that significantly impact hearing health. This year’s event highlighted numerous advanced technologies from global companies, competing across eight categories.
Dr. Robert Traynor, a member of the 2024 Awards judging panel, stated, “The Innovator Awards are designed to spotlight the visionaries and companies that transform cutting-edge hearing technology into practical solutions.”
René Govaerts, President & General Manager of Oticon Medical, expressed his pride in the achievement: “Winning the Innovator Award for the Sentio System is a remarkable recognition of our dedication to advancing hearing health technology. This accolade validates the hard work and commitment of our team to enhance the quality of life for individuals with hearing challenges.”
The Sentio System, Oticon Medical’s first active transcutaneous bone conduction hearing system, represents a significant leap in hearing technology. The system is part of a comprehensive product portfolio designed to accommodate various reimbursement systems worldwide, adapting to diverse clinical settings and meeting the specific needs of patients with different indications.
For further details about the Sentio System, visit Oticon Medical’s website.
The Hearing Technology Innovator Awards aim to honour the most innovative and effective solutions in the hearing technology field, recognising the significant contributions of companies like Oticon Medical. The Sentio System’s success in this prestigious competition underscores Oticon Medical’s role as a leader in hearing health innovation.
Please note that product availability and indications may vary by market and are subject to regulatory approval.